Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Stifel 2024 Healthcare Conference on
Tuesday, November 19 th-
Company presentation -
Tuesday, November 19 th starting at10:20 a.m. ET
-
Company presentation -
-
7th Annual
Evercore HealthCONx Conference onTuesday, December 3 rd-
Company presentation -
Tuesday, December 3 rd starting at2:10 p.m. ET
-
Company presentation -
-
Citi’s 2024 Global Healthcare Conference on
Wednesday, December 4 th
Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.
About
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Lastly, chenodiol, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023. Mirum has submitted a new drug application with the FDA for the approval of chenodiol to treat CTX in the
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107101895/en/
Investors:
ir@mirumpharma.com
Media:
media@mirumpharma.com
Source: